Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Stake Raised by Cwm LLC

CWM LLC boosted its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 26.3% during the 1st quarter, according to its most recent disclosure with the SEC. The firm owned 16,664 shares of the biopharmaceutical company's stock after buying an additional 3,473 shares during the period. CWM LLC's holdings in Alnylam Pharmaceuticals were worth $4,500,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of the business. Park Square Financial Group LLC purchased a new stake in shares of Alnylam Pharmaceuticals during the fourth quarter valued at approximately $28,000. Whipplewood Advisors LLC raised its stake in shares of Alnylam Pharmaceuticals by 208.8% during the first quarter. Whipplewood Advisors LLC now owns 105 shares of the biopharmaceutical company's stock valued at $28,000 after purchasing an additional 71 shares during the period. Bessemer Group Inc. raised its stake in shares of Alnylam Pharmaceuticals by 176.9% during the first quarter. Bessemer Group Inc. now owns 108 shares of the biopharmaceutical company's stock valued at $29,000 after purchasing an additional 69 shares during the period. Colonial Trust Co SC purchased a new stake in shares of Alnylam Pharmaceuticals during the fourth quarter valued at approximately $35,000. Finally, Washington Trust Advisors Inc. raised its stake in shares of Alnylam Pharmaceuticals by 53.5% during the first quarter. Washington Trust Advisors Inc. now owns 175 shares of the biopharmaceutical company's stock valued at $47,000 after purchasing an additional 61 shares during the period. Hedge funds and other institutional investors own 92.97% of the company's stock.

Alnylam Pharmaceuticals Price Performance

ALNY stock traded down $4.16 during trading on Friday, hitting $320.53. The company had a trading volume of 581,106 shares, compared to its average volume of 852,651. The firm has a market capitalization of $41.79 billion, a price-to-earnings ratio of -153.36 and a beta of 0.23. The business has a 50 day moving average of $305.09 and a 200 day moving average of $270.94. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $205.87 and a fifty-two week high of $333.70. The company has a current ratio of 3.04, a quick ratio of 2.98 and a debt-to-equity ratio of 8.88.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The biopharmaceutical company reported ($0.44) earnings per share for the quarter, missing the consensus estimate of ($0.37) by ($0.07). The company had revenue of $594.19 million during the quarter, compared to analyst estimates of $584.32 million. Alnylam Pharmaceuticals had a negative return on equity of 510.31% and a negative net margin of 11.49%. The business's revenue for the quarter was up 20.2% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.16) EPS. As a group, research analysts predict that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Insiders Place Their Bets

In related news, CEO Yvonne Greenstreet sold 19,297 shares of the company's stock in a transaction dated Monday, June 2nd. The shares were sold at an average price of $306.00, for a total value of $5,904,882.00. Following the completion of the sale, the chief executive officer owned 48,948 shares of the company's stock, valued at $14,978,088. This represents a 28.28% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 1.50% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on ALNY. Wells Fargo & Company lifted their price target on shares of Alnylam Pharmaceuticals from $287.00 to $333.00 and gave the stock an "equal weight" rating in a research note on Monday, June 30th. BMO Capital Markets lifted their price target on shares of Alnylam Pharmaceuticals from $300.00 to $360.00 and gave the stock an "outperform" rating in a research note on Tuesday, June 24th. Morgan Stanley dropped their price target on shares of Alnylam Pharmaceuticals from $284.00 to $268.00 and set an "equal weight" rating for the company in a research note on Friday, April 11th. Stifel Nicolaus lifted their price target on shares of Alnylam Pharmaceuticals from $300.00 to $345.00 and gave the stock a "buy" rating in a research note on Monday, March 31st. Finally, Royal Bank Of Canada lifted their price target on shares of Alnylam Pharmaceuticals from $310.00 to $330.00 and gave the stock an "outperform" rating in a research note on Friday, March 21st. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and twenty-two have assigned a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $346.13.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.